2型糖尿病合并代谢相关脂肪性肝病的研究进展

Research progress of type 2 diabetes mellitus combined with metabolic-associated fatty liver disease

目前,2型糖尿病(T2DM)发病率逐年上升,并且由于该疾病属于慢性代谢性疾病,致使人体内的各种物质及能量代谢发生障碍,其中最主要的是以糖类物质为首的代谢功能紊乱,继而引发脂质代谢紊乱。而人体的脂质代谢主要场所发生在肝脏,故脂质大量在肝脏蓄积,长此以往造成肝脏损害,如脂肪肝等疾病。现今国际专家共识提出了代谢相关脂肪性肝病(MAFLD)。据不完全统计,目前全球近25%的T2DM患者都会患有MAFLD。综上所述,T2DM和MAFLD的发病机制相互联系作用与发展,且目前并没有完全可靠的实验室数据证明治疗T2DM合并MAFLD的有效药物。本文从发病机制及相关治疗药物进行阐述,为发现预防、诊断和治疗T2DM合并MAFLD的新思路提供参考。

At present,the incidence rate of type 2 diabetes mellitus(T2DM)is increasing year by year.As the disease is a chronic metabolic disease,it may cause substance and energy metabolism disorders of all kinds in the human body,with metabolic disorders caused by carbohydrates as the most important manifestations,which will then lead to lipid metabolism disorders.The lipid metabolism in the human body mainly occurs in the liver,so a large number of lipids accumulate in the liver,causing damage to the liver over time,such as fatty liver and other diseases.Nowadays,international expert consensuses have proposed metabolic-associated fatty liver disease(MAFLD).According to incomplete statistics,nearly 25%of T2DM patients worldwide currently suffer from MAFLD.In summary,the pathogenesis and development of T2DM and MAFLD are interrelated,and there is currently no fully reliable laboratory data to prove the effectiveness of drugs for the treatment of T2DM combined with MAFLD.This article elaborates on the pathogenesis and related therapeutic drugs,in order to discover new ideas for prevention,diagnosis,and treatment of T2DM combined with MAFLD for reference.